سال 10، شماره 37 - ( English 1389 )                   سال 10 شماره 37 صفحات 130-121 | برگشت به فهرست نسخه ها

XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mansoori P, Akhondzadeh S, Raisi F, Ghaeli P, Jamshidi A, Nasehi A, et al . A Randomized, Double-blind, Placebo - controlled Study of Safety of the Adjunctive Saffron on Sexual Dysfunction Induced by a Selective Serotonin Reuptake Inhibitor. J. Med. Plants 2011; 10 (37) :121-130
URL: http://jmp.ir/article-1-239-fa.html
Mansoori P، Akhondzadeh S، Raisi F، Ghaeli P، Jamshidi AH، Nasehi AA، و همکاران.. A Randomized, Double-blind, Placebo - controlled Study of Safety of the Adjunctive Saffron on Sexual Dysfunction Induced by a Selective Serotonin Reuptake Inhibitor. فصلنامه گياهان دارویی 1389; 10 (37) :130-121

URL: http://jmp.ir/article-1-239-fa.html


1- School of Pharmacy, Tehran University of Medical Sciences
2- School of Pharmacy, Tehran University of Medical Sciences ، mmppg@yahoo.com
3- Department of Pharmacognosy and Pharmaceutics, Institute of Medicinal Plants, ACECR
چکیده:   (4976 مشاهده)
Background: Recent studies have indicated potential of saffron for applying in a wide variety of diseases such as psychiatric and neurologic disorders. The concurrent use of saffron with SSRIs can lead to reducing the dose of SSRIs. Saffron at a dose of 200 mg may change some hematological and biochemical parameters. Objective: The goal of this trial was to assess the safety of concomitant administration of saffron and SSRI in patients with major depressive disorder (MDD). Methods: Twenty adult outpatients between 18 to 55 years-old with the diagnosis of MDD who were receiving an SSRI for at least 1 month prior to the initiation of the study entered this double-blind trial. They were randomly assigned to receive capsule of saffron (15 mg twice daily) or placebo. Some laboratory parameters were measured at baseline and week 4 of the study. Other side effects checked on a prepared list of side effects, were systematically recorded throughout the study at baseline and on a weekly basis. Results: Saffron as an add-on medication to SSRIs for 4 weeks did not cause any statistically significant changes in laboratory parameters including AST, ALT, ALP, BUN, Cr., FBS, TG, TC, WBC, RBC, Hgb, Ht, PT, INR, and Pl count. Conclusion: This preliminary study provides safety evidences of concurrent intake of saffron and SSRI.
واژه‌های کلیدی: Saffron، <، i>، Crocus sativus<، /i>، Adverse effects، SSRI، MDD
متن کامل [PDF 185 kb]   (1889 دریافت)    
نوع مطالعه: مروری | موضوع مقاله: فارماكولوژی و سم شناسی
دریافت: 1389/10/18 | پذیرش: 1389/12/18 | انتشار: 1389/12/27

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA

ارسال پیام به نویسنده مسئول


بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به فصلنامه علمی پژوهشی گیاهان دارویی می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2023 CC BY-NC 4.0 | Journal of Medicinal Plants

Designed & Developed by : Yektaweb